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Sepsis Associated with Dermatologic Hospitalization Is not the
Cause of High Mortality of Bullous Pemphigoid in Europe
To the Editor:
Colbert et al (2004) have hypothesized that sepsis induced
by hospitalization for bullous pemphigoid can be the cause
of the difference in mortality rates between US and Europe.
After their report, we performed a study to describe the
prognosis of our patients and to check whether the time
course of events supports their hypothesis.
We collected all bullous pemphigoid diagnoses from the
dermatopathology files of our secondary care department
(1998–2003, n¼ 31). Inclusion criteria were: newly diag-
nosed patients, coming from the area of 300,000 inhabit-
ants assigned to our hospital, with histopathology findings
in agreement with the diagnosis of pemphigoid, and meet-
ing the French Bullous Study Group criteria for diagnosis of
bullous pemphigoid (Vaillant et al, 1998; Joly et al, 2004) that
we incorporated in clinical practice in 1998. We performed
direct immunofluorescence in 10 patients with positive re-
sults in all of them. Three patients who did not fulfill diag-
nostic criteria, and two who were not new diagnoses, were
excluded from the study. We collected data on all hospital
admissions for bullous pemphigoid (all to the dermatology
department) and patient evolution. Admissions because of
other disorders were not considered to be relevant to the
tested hypothesis and were not registered. All patients in-
cluded in the study (n¼ 26) or their families were contacted
either in the clinical setting or by telephone call.
Statistical analyses were performed using SPSS soft-
ware (version 10). To calculate standardized mortality ratio
(SMR), we used population data obtained from ‘‘Instituto
Nacional de Estadı´stica’’ (Galicia, 1998–1999).
The mean age of patients at diagnosis was 77 y (range:
57–96 y). They were treated with oral corticosteroids
(n¼ 14), or topical corticosteroids (n¼12). For patients
treated with oral prednisone, the mean daily dose was 34
mg at start of therapy (standard deviation (SD): 9.8) (range:
20–50). In those alive at the end of therapy, the mean length
of therapy was 20 mo (SD: 12). All patients in the topical
corticosteroid group started with a dose of 30 g per d
0.05% clobetasol propionate (Clovate, Celltech Pharma
Spain) in a single application. Most of the 26 patients suf-
fered from other disorders: cerebrovascular disease (9),
dementia (8), diabetes (5), neoplasia (4), cardiac disorders
(4), decubitus ulcers (4), and limb ischemia (2). Only six pa-
tients had no other disorder but pemphigoid.
At the time of data collection 15 patients were alive and
11 were dead. The mean and median follow-up were 22 and
14 mo. Death rates were 16% at 3 mo (95% confidence
interval (CI), 7%–39%), 21% at 6 mo (95% CI, 10%–44%),
and 40% at 1 y (95% CI, 23%–63%). Age- and gender-
adjusted mortality rate at 1 y was two times higher in pe-
mphigoid patients than in the general population of our area
(SMR: 2.15; 95% CI, 1.07–3.84; p¼0.016). Hazard rate
plotting showed that the risk of death was higher in the first
year after diagnosis. Almost all patients were hospitalized
shortly after the diagnosis of bullous pemphigoid (only one
patient was admitted 3 mo later). The time course of events
is plotted in Fig 1. The mean time from patient discharge
from the dermatology department to death was 13 mo (SD:
11) (range: 0.5–36). We found no differences in the number
of days of hospitalizations between patients dying or sur-
viving (t test, 95% CI: 10 to 5 d; p¼0.46). Two patients
died 2 wk after discharge from hospital: one had metastatic
adenocarcinoma and the other died of pneumonia. The rest
of the patients died at least 6 wk after discharge. The
causes of death were neoplasia (2), sepsis (2), pneumonia
(2), cerebrovascular accident (1), myocardial infarction (1),
and unknown (1).
The prognosis of bullous pemphigoid is an area of de-
bate (Colbert et al, 2004; Swerlick and Korman, 2004). Our
findings support, in a different setting, previous descriptions
of pemphigoid as a severe disease, with around 40% of
patients dying within 12 mo. Other relevant findings were
that hospital admission to dermatology is routine in our
setting after a diagnosis of pemphigoid, readmissions are
exceptional, and this high mortality does not take place
within periods of dermatological hospitalization or close
to them.
Our data fail to support the hypothesis of hospitalization
as a cause of increased incidence of sepsis and mortality,
as the long interval between hospitalization and death can-
not be properly explained.
We do not think that selection bias is the cause of the
high mortality observed in our series. To avoid this, we re-
cruited every patient with a biopsy-proved diagnosis, not
just patients with generalized disease. We excluded the rare
patients not coming from the area assigned to our hospital
(Dermatological National Health Service care is divided in
areas in Spain). An indicator of the absence of a marked
selection bias was that co-morbidities of our patients were
similar to those in other series. Moreover, we have probably
received the majority of patients from our area. If we ac-
cept an incidence of seven cases per million per yearAbbreviations: CI, confidence interval; SD, standard deviation
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(Wojnarowska et al, 2002), approximately 13 cases would
be expected during the study period. The fact that many of
our patients were treated with topical corticosteroids could
also be a cause of bias. This therapy, however, has been
shown to actually improve prognosis (Joly et al, 2002);
therefore, it should not account for the high rate of mortality
observed.
The main limitation of our study is the lack of immuno-
fluorescence confirmation of the diagnosis in many pa-
tients. But we have used biopsy information, and clinical
criteria that have been well validated. Our data confirm the
grim prognosis of bullous pemphigoid patients in European
series, but refute Colbert’s et al hypothesis of this mortality
being caused by sepsis associated with the different hos-
pitalization pattern.
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Figure 1
Evolution of patients. Each patient evo-
lution is represented in a horizontal line
where admissions for bullous pemphigoid
are represented by rectangles, deaths by
black rhombus, and other causes of end
of follow-up by white rhombus. Those
patients with follow-ups longer than 18
mo have a rhombus in the right border
with the length of follow-up attached.
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